DK43188A - Hepatitis b-virus overfladeantigener og hybridantigener indeholdende dem - Google Patents

Hepatitis b-virus overfladeantigener og hybridantigener indeholdende dem

Info

Publication number
DK43188A
DK43188A DK043188A DK43188A DK43188A DK 43188 A DK43188 A DK 43188A DK 043188 A DK043188 A DK 043188A DK 43188 A DK43188 A DK 43188A DK 43188 A DK43188 A DK 43188A
Authority
DK
Denmark
Prior art keywords
hepatitis
surface antigen
virus surface
antigens containing
hybrid antigens
Prior art date
Application number
DK043188A
Other languages
Danish (da)
English (en)
Other versions
DK43188D0 (da
Inventor
Teresa Gabezon
Michel De Wilde
Nigel Harford
Original Assignee
Smith Kline Rit
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smith Kline Rit filed Critical Smith Kline Rit
Publication of DK43188D0 publication Critical patent/DK43188D0/da
Publication of DK43188A publication Critical patent/DK43188A/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/78—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Pseudomonas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
DK043188A 1987-01-30 1988-01-28 Hepatitis b-virus overfladeantigener og hybridantigener indeholdende dem DK43188A (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US932587A 1987-01-30 1987-01-30

Publications (2)

Publication Number Publication Date
DK43188D0 DK43188D0 (da) 1988-01-28
DK43188A true DK43188A (da) 1988-07-31

Family

ID=21736956

Family Applications (1)

Application Number Title Priority Date Filing Date
DK043188A DK43188A (da) 1987-01-30 1988-01-28 Hepatitis b-virus overfladeantigener og hybridantigener indeholdende dem

Country Status (20)

Country Link
EP (1) EP0278940A3 (pt)
JP (1) JPS6463382A (pt)
KR (1) KR880009130A (pt)
CN (1) CN1031395A (pt)
AP (1) AP56A (pt)
AU (1) AU1093088A (pt)
DD (3) DD284899A5 (pt)
DK (1) DK43188A (pt)
FI (1) FI880428A (pt)
HU (1) HUT50876A (pt)
IL (1) IL85216A0 (pt)
MA (1) MA21169A1 (pt)
NO (1) NO880395L (pt)
NZ (1) NZ223297A (pt)
OA (1) OA08801A (pt)
PT (1) PT86640B (pt)
SU (1) SU1746887A3 (pt)
TN (1) TNSN88004A1 (pt)
YU (1) YU17488A (pt)
ZA (1) ZA88488B (pt)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988010300A1 (en) * 1987-06-22 1988-12-29 Medico Labs Ag Heterologous viral peptide particle immunogens
IL89991A0 (en) * 1988-04-25 1989-12-15 Phillips Petroleum Co Expression of hepatitis b pres2 protein in methylotrophic yeasts
EP0345792A3 (en) * 1988-06-10 1991-05-02 F. Hoffmann-La Roche Ag Htlv-i / hiv-1 fusion proteins
FR2635532B1 (fr) * 1988-07-29 1992-05-22 Pasteur Institut Particules hbsag recombinantes hybrides : caracteristiques morphologiques de l'antigene hbsag contenant 1 sequence immunogene induisant des anticorps neutralisants diriges contre hiv ou susceptible d'etre reconnue par de tels anticorps; sequences nucleotidiques codant pour de telles particules; vaccins les contenant
US5130247A (en) * 1989-09-19 1992-07-14 Merck & Co., Inc. Expression of fusion protein of HIV envelope and HBsAG
EP0421626A1 (en) * 1989-09-19 1991-04-10 Merck & Co. Inc. Vaccine for aids and hepatitis B
US5130248A (en) * 1989-09-19 1992-07-14 Merck & Co., Inc. Expression of fusion protein of HIV envelope and HBsAg
EP0491077A1 (en) * 1990-12-19 1992-06-24 Medeva Holdings B.V. A composition used as a therapeutic agent against chronic viral hepatic diseases
EP0614465B1 (en) * 1991-11-16 1999-03-17 SMITHKLINE BEECHAM BIOLOGICALS s.a. HYBRID PROTEIN BETWEEN CS FROM PLASMODIUM AND HBsAG
CA2124928C (en) * 1991-12-23 2003-06-17 Bruce D. Irvine Hbv amplifier probes for use in solution phase sandwich hybridization assays
US6297048B1 (en) 1992-02-04 2001-10-02 Chiron Corporation Hepatitis therapeutics
US6169171B1 (en) 1992-02-27 2001-01-02 Smithkline Beecham Biologicals (S.A.) Hybrid protein between CS from plasmodium and HBSAG
US5928902A (en) * 1992-02-27 1999-07-27 Smithkline Beecham Biologicals (S.A.) Hybrid protein between CS from plasmodium and HBsAg
US6667387B1 (en) 1996-09-30 2003-12-23 N.V. Innogenetics S.A. HCV core peptides
US6709828B1 (en) 1992-03-06 2004-03-23 N.V. Innogenetics S.A. Process for the determination of peptides corresponding to immunologically important epitopes and their use in a process for determination of antibodies or biotinylated peptides corresponding to immunologically important epitopes, a process for preparing them and compositions containing them
US6165730A (en) * 1992-03-06 2000-12-26 N.V. Innogenetics S.A. Hepatitis C virus peptides obtained from the NS4 coding region and their use in diagnostic assays
WO1993020840A1 (en) * 1992-04-14 1993-10-28 British Bio-Technology Limited Induction of ctl responses
EP0642355B1 (en) 1992-05-23 1998-07-15 SMITHKLINE BEECHAM BIOLOGICALS s.a. Combined vaccines comprising hepatitis b surface antigen and other antigens
CN1063343C (zh) * 1993-04-27 2001-03-21 中国科学院上海生物化学研究所 氨端带前表面抗原决定簇的乙型肝炎表面抗原蛋白
US6235888B1 (en) 1994-10-05 2001-05-22 The General Hospital Corporation Hepatitis C virus vaccine
RU2189254C2 (ru) * 1995-06-06 2002-09-20 Америкэн Хоум Продактс Корпорэйшн Вакцины против вирусов гепатита
DE69738521T2 (de) 1996-04-05 2009-05-07 Novartis Vaccines and Diagnostics, Inc., Emeryville Alphaviren-vektors mit einer reduzierten inhibierung der synthese von zellmakromolekülen
CA2266656A1 (en) 1996-09-17 1998-03-26 Chiron Corporation Compositions and methods for treating intracellular diseases
GB9623233D0 (en) 1996-11-07 1997-01-08 Smithkline Beecham Biolog Vaccine composition
EP2266604A3 (en) 1998-10-16 2011-05-11 GlaxoSmithKline Biologicals S.A. Adjuvant systems and vaccines
UA79735C2 (uk) 2000-08-10 2007-07-25 Глаксосмітклайн Байолоджікалз С.А. Очищення антигенів вірусу гепатиту b (hbv) для використання у вакцинах
CN100381171C (zh) * 2004-12-30 2008-04-16 成都生物制品研究所 含前s1、前s2和s抗原决定簇的乙肝表面抗原复合颗粒
CN102675430B (zh) * 2005-08-12 2014-08-27 上海贺普药业股份有限公司 乙型肝炎病毒表面l蛋白相关肽
BRPI0708865A8 (pt) 2006-03-14 2019-01-22 Univ Oregon Health & Science métodos para produzir uma resposta imune à tuberculose
EP2066344B2 (en) 2006-09-07 2016-06-29 GlaxoSmithKline Biologicals S.A. Inactivated Poliovirus combination vaccine
KR100836745B1 (ko) * 2007-01-31 2008-06-10 (주)두비엘 Ｈｂｖ 백신 및 그의 제조 방법
AU2008221383B2 (en) 2007-02-28 2012-09-13 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Brachyury polypeptides and methods for use
UY31064A1 (es) 2007-05-02 2009-01-05 Glaxosmithkline Biolog Sa Vacuna
US9415006B2 (en) 2008-05-23 2016-08-16 The Regents Of The University Of Michigan Immunogenic compositions comprising nanoemulsion and hepatitis B virus immunogen and methods of using the same
WO2010099472A2 (en) 2009-02-27 2010-09-02 The U.S.A. Of America, As Represented By The Secretary, Department Of Health And Human Services Spanx-b polypeptides and their use
GB201105981D0 (en) 2011-04-08 2011-05-18 Glaxosmithkline Biolog Sa Novel process
ES2752190T3 (es) 2012-09-14 2020-04-03 Us Health Proteína Brachyury, vectores adenovirales que codifican proteína Brachyury y su uso
CA2994694A1 (en) 2015-08-03 2017-02-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Brachyury deletion mutants, non-yeast vectors encoding brachyury deletion mutants, and their use

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2145092B (en) * 1983-01-28 1988-04-07 Univ New York Protective peptide antigen
IL69202A (en) * 1982-09-08 1991-08-16 Smith Kline Rit Surface antigen polypeptides of hbv virus produced in yeast and the preparation thereof
EP0174444B1 (en) * 1984-06-18 1992-03-11 Chiron Corporation Hepatitis surface antigen particle vaccine
EP0171908A3 (en) * 1984-07-11 1987-07-15 Takeda Chemical Industries, Ltd. Hepatitis b virus surface antigen and production thereof
GB8421282D0 (en) * 1984-08-22 1984-09-26 Connaught Lab Multispecific antigenic proteins
EP0175261B1 (en) * 1984-09-12 1991-12-11 Chiron Corporation Hybrid particle immunogens
EP0180012A1 (de) * 1984-10-27 1986-05-07 Wolfram H. Prof. Dr. Gerlich Immunogene Polypeptidsequenz des Hepatitis B-Virus
CN86100979A (zh) * 1985-02-07 1986-12-17 史密丝克莱恩贝克曼公司 疟疾疫苗的制备方法
US4774175A (en) * 1985-03-01 1988-09-27 Centocor, Inc. Immunochemical methods for the detection of antibody against HTLV-III
US4683294A (en) * 1985-04-03 1987-07-28 Smith Kline Rit, S.A. Process for the extraction and purification of proteins from culture media producing them
WO1986006077A1 (en) * 1985-04-08 1986-10-23 Amgen A method and a hybrid promoter for controlling exogenous gene transcription
FR2581394B1 (fr) * 1985-05-02 1988-08-05 Grp Genie Genetique Particules ayant les proprietes immunogenes de l'antigene hbs et portant un site antigenique etranger aux epitopes portes par l'antigene hbs, vecteurs et cellules animales pour la production de telles particules et compositions contenant de telles particules pour la production de vaccins mixtes
US4816564A (en) * 1986-01-31 1989-03-28 Merck & Co., Inc. Method for producing hepatitis B virus proteins in yeast
CA1310602C (en) * 1986-06-03 1992-11-24 Hajime Horii Yeast promoter and process for preparing heterologous protein

Also Published As

Publication number Publication date
YU17488A (en) 1991-02-28
DD284899A5 (de) 1990-11-28
HUT50876A (en) 1990-03-28
DD285612A5 (de) 1990-12-19
SU1746887A3 (ru) 1992-07-07
PT86640A (pt) 1988-02-01
MA21169A1 (fr) 1988-10-01
IL85216A0 (en) 1988-07-31
OA08801A (fr) 1989-03-31
FI880428A (fi) 1988-09-13
EP0278940A3 (en) 1988-12-07
DD285994A5 (de) 1991-01-10
KR880009130A (ko) 1988-09-14
FI880428A0 (fi) 1988-01-29
AU1093088A (en) 1988-08-04
DK43188D0 (da) 1988-01-28
JPS6463382A (en) 1989-03-09
NO880395L (no) 1988-08-01
AP8800078A0 (en) 1987-11-01
ZA88488B (en) 1988-10-26
PT86640B (pt) 1992-01-31
NZ223297A (en) 1991-06-25
NO880395D0 (no) 1988-01-29
AP56A (en) 1989-09-26
CN1031395A (zh) 1989-03-01
EP0278940A2 (en) 1988-08-17
TNSN88004A1 (fr) 1990-07-10

Similar Documents

Publication Publication Date Title
DK43188D0 (da) Hepatitis b-virus overfladeantigener og hybridantigener indeholdende dem
FI945483A0 (fi) Hepatiitti B - pinta-antigeenejä ja muita antigeenejä sisältäviä yhdistelmärokotteita
IT1198289B (it) Antigene di flavvirus
PT85137A (en) T and b cell epitopes of the pre-s region of hepatitis b virus surface antigen
DK190889D0 (da) Antigen
KR890701743A (ko) B형 간염 표면 항원 백신
GB8816233D0 (en) Rubella e1 glycoprotein antigens
IL81920A (en) Vaccines comprising an antigen and interferon-ypsilon and their preparation
GB2200638B (en) Babesia divergens antigen and vaccine
GB8703864D0 (en) Bluetongue virus antigens
GB8709779D0 (en) Bluetongue virus antigens
IE880458L (en) Virus antigen
ZA874498B (en) T and b cell epitopes of the pre-s region of hepatitis b virus surface antigen
GB8621578D0 (en) Hepatitis b viral antigens
IE871644L (en) T and b cell epitopes of the pre-s region of hepatitis b¹virus surface antigen
GB8708532D0 (en) Particulate hybrid hiv antigens
IE861419L (en) Isolation of hepatitis b surface antigen
GB8622883D0 (en) Expression of hepatitis b viral antigens
IE882549L (en) Carrier of antigen or antibody
IE851705L (en) Hepatitis B Virus Surfact Antigen and Production Thereof
GB8716044D0 (en) Rubella e1 glyco-protein antigens
IE880549L (en) Purifying hepatitis b antigen from yeast
GB8621240D0 (en) Antigens
DK303089D0 (da) Antigener

Legal Events

Date Code Title Description
AHB Application shelved due to non-payment